Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapirolizumab pegol for moderately to severely active systemic lupus erythematosus
2023-508191-11-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Nov 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Dapirolizumab pegol + standard of care with Placebo + standard of care (2 arms). Primary endpoint: BICLA response at Week 48. Planned start Nov 2024; status: authorised.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-508191-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508191-11-00.